465 related articles for article (PubMed ID: 31242658)
1. Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis.
Zhang J; Tang PMK; Zhou Y; Cheng ASL; Yu J; Kang W; To KF
Cells; 2019 Jun; 8(6):. PubMed ID: 31242658
[TBL] [Abstract][Full Text] [Related]
2. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
3. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
4. FGF signaling network in the gastrointestinal tract (review).
Katoh M; Katoh M
Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer.
Shin EY; Lee BH; Yang JH; Shin KS; Lee GK; Yun HY; Song YJ; Park SC; Kim EG
J Cancer Res Clin Oncol; 2000 Sep; 126(9):519-28. PubMed ID: 11003564
[TBL] [Abstract][Full Text] [Related]
7. FGF/FGFR signaling in bone formation: progress and perspectives.
Marie PJ; Miraoui H; Sévère N
Growth Factors; 2012 Apr; 30(2):117-23. PubMed ID: 22292523
[TBL] [Abstract][Full Text] [Related]
8. [FGF/FGFR signalling: Implication in oncogenesis and perspectives].
Flippot R; Kone M; Magné N; Vignot S
Bull Cancer; 2015 Jun; 102(6):516-26. PubMed ID: 25986739
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
10. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
12. Therapeutics Targeting FGF Signaling Network in Human Diseases.
Katoh M
Trends Pharmacol Sci; 2016 Dec; 37(12):1081-1096. PubMed ID: 27992319
[TBL] [Abstract][Full Text] [Related]
13. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p.
Zhang J; Zhou Y; Huang T; Wu F; Pan Y; Dong Y; Wang Y; Chan AKY; Liu L; Kwan JSH; Cheung AHK; Wong CC; Lo AKF; Cheng ASL; Yu J; Lo KW; Kang W; To KF
Oncogene; 2019 Jan; 38(1):33-46. PubMed ID: 30082912
[TBL] [Abstract][Full Text] [Related]
14. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
15. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention.
Mahapatra S; Jonniya NA; Koirala S; Ursal KD; Kar P
J Biomol Struct Dyn; 2023; 41(22):13509-13533. PubMed ID: 36995019
[TBL] [Abstract][Full Text] [Related]
16. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
17. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.
Tamburello M; Altieri B; Sbiera I; Sigala S; Berruti A; Fassnacht M; Sbiera S
Endocrine; 2022 Sep; 77(3):411-418. PubMed ID: 35583844
[TBL] [Abstract][Full Text] [Related]
18. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
19. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]